-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
CNS Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to Q3 2025.
- CNS Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $34.9K, a 52% increase year-over-year.
- CNS Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $129K, a 426% increase year-over-year.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $44.1K, a 218% increase from 2023.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $13.9K.
- CNS Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$7.03K, a 24.3% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)